|
| |
VaxGen Inc.VaxGen Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease. Founded in 1995, VaxGen’s business strategy emphasizes the development and commercialization of vaccine candidates for the prevention of potential bioterrorism threats, specifically anthrax and smallpox. Our longer-term strategy entails leveraging our expertise and infrastructure to expand our product portfolio beyond biodefense vaccines and into commercial biologic products.
On November 4, 2004 VaxGen announced the U.S. government award of an $877.5 million contract to supply 75 million doses of anthrax vaccine for civilian defense.
To date, we have in-licensed all of our product candidates at little or no expense to the company. Although we focus on biologic products for the treatment and prevention of human infectious diseases and have significant experience with vaccines and advanced biopharmaceutical manufacturing, we are not wedded to any particular platform technology. We believe this strategy allows us to move quickly and opportunistically to take advantage of promising new products that serve important medical needs.
| Contact Details: |
| 1000 Marina BoulevardSuite 200 |
| Brisbane |
| California |
| 94005 |
| United States of America |
| Tel: | (650) 624-1000 |
| Fax: | (650) 624-1001 |
| Email: | |
| WWW: | www.vaxgen.com/
|
|
Loading...
|
Recent Publications by VaxGen Inc.: |  |
LC16m8: an attenuated smallpox vaccine.
The frequency of moderate to severe adverse reactions associated with... | 5th January, 2007
|
| Vaccine. 2006 Nov 17;24(47-48):7009-22. Epub 2006 Apr 21.
DOI Direct Link |
High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a Phase 3 vaccine efficacy trial.
During the course of a large-scale HIV-1 vaccine field trial (VAX004),... | 9th December, 2006
| VaxGen Inc., South San Francisco, California 94080, USA.
| AIDS Res Hum Retroviruses. 2006 Oct;22(10):1014-21.
DOI Direct Link |
Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
The possible reemergence of smallpox through bioterrorism requires the... | 16th June, 2006
| VaxGen Inc., 347 Oyster Point Boulevard, Suite 102, South San Francisco,
| Vaccine. 2006 Apr 24;24(17):3686-94.
DOI Direct Link |
Press Releases on VaxGen Inc.:
|
 |
| VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment |
27th August, 2008 |
VaxGen, Inc. |
SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- VaxGen,
Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided a
financial and operational update since the
|
| VaxGen Receives Repayment in Full of Bridge Loan to Raven biotechnologies |
17th July, 2008 |
VaxGen, Inc. |
SOUTH SAN FRANCISCO, Calif., July 17 /PRNewswire-FirstCall/ -- VaxGen,
Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today announced
that it has received repayment in full,
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 368 times since April 2007, the link to the organisation's website has been followed 71 times Recent Search Terms used to find this page: vaxgen fax | Vaxgen Inc | . Search for more companies in Brisbane Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for VaxGen Inc. |
